Cabozantinib is a product developed and produced by which company?

Cabozantinib is a product developed byExelixis, Inc. (Exelixis). Exelixis is an American biotechnology company founded in 1994 and headquartered in Alameda, California (Alameda, California). The company focuses on the field of cancer treatment and is committed to developing innovative anti-cancer drugs.

Cabotinib is an important drug of Exelixis. After years of clinical research and development, it has been approved by relevant countries and is widely used to treat various cancers such as renal cell carcinoma, thyroid cancer and hepatocellular carcinoma. The drug plays an important role in anti-cancer therapy and provides patients with new treatment options.

The main mechanism of action of cabozantinib is to inhibit multiple tyrosine kinases, which play important roles in tumor growth, angiogenesis and metastasis. By interfering with these key signaling pathways, cabozantinib inhibits tumor growth and spread.

Cabozantinib is not currently on the market in China and is therefore not included in medical insurance because it requires approval from the National Medical Products Administration. Therefore, patients cannot purchase it domestically and need to purchase it through overseas channels. There are original and generic cabozantinib drugs abroad. The original drugs are mainly Japanese original drugs, Turkish original drugs and European original drugs. The price is relatively high, ranging from 35,000 to 46,000 yuan. Foreign generic drugs are mainly Lao generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan. The price is much cheaper than original drugs and is more suitable for the needs of patients in ordinary families. The ingredients of original drugs and generic drugs are basically the same.